Compare BMRA & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRA | BRTX |
|---|---|---|
| Founded | 1971 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.1M |
| IPO Year | 1995 | 2015 |
| Metric | BMRA | BRTX |
|---|---|---|
| Price | $1.58 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 353.7K |
| Earning Date | 04-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,311,000.00 | $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.45 | $0.16 |
| 52 Week High | $3.58 | $1.89 |
| Indicator | BMRA | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 38.82 |
| Support Level | N/A | $0.23 |
| Resistance Level | $1.75 | $0.31 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 56.52 | 37.63 |
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.